Hologic, Inc. $HOLX Holdings Raised by Wealthfront Advisers LLC

Wealthfront Advisers LLC increased its stake in Hologic, Inc. (NASDAQ:HOLX) by 76.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,640 shares of the medical equipment provider’s stock after purchasing an additional 34,557 shares during the quarter. Wealthfront Advisers LLC’s holdings in Hologic were worth $5,189,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Chung Wu Investment Group LLC purchased a new position in shares of Hologic in the second quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd boosted its stake in Hologic by 193.6% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 273 shares during the period. Zions Bancorporation National Association UT purchased a new position in Hologic during the 1st quarter worth approximately $34,000. Cromwell Holdings LLC raised its stake in Hologic by 307.0% during the 2nd quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after purchasing an additional 436 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Hologic in the first quarter valued at $42,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of several recent analyst reports. Leerink Partners upped their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a research report on Tuesday, October 21st. UBS Group upped their target price on Hologic from $65.00 to $70.00 and gave the company a “neutral” rating in a report on Thursday, July 31st. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Hologic in a research report on Wednesday, October 8th. Finally, BTIG Research reiterated a “neutral” rating on shares of Hologic in a research report on Tuesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of “Hold” and an average price target of $79.23.

Insider Buying and Selling

In related news, Director Christiana Stamoulis sold 7,402 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the sale, the director directly owned 47,336 shares in the company, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Stephen P. Macmillan sold 138,358 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The SEC filing for this sale provides additional information. 1.88% of the stock is currently owned by company insiders.

Hologic Trading Up 0.1%

Shares of NASDAQ:HOLX opened at $74.01 on Wednesday. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $16.46 billion, a PE ratio of 30.71, a P/E/G ratio of 2.54 and a beta of 0.63. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The firm has a fifty day moving average price of $67.91 and a 200 day moving average price of $64.25.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the company earned $1.06 earnings per share. The business’s revenue was up 1.2% compared to the same quarter last year. Analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.